At the San Antonio Breast Cancer Symposium, researchers presented findings on Clarity BCR, a multimodal multitask ...

A discovery in mice reveals why fasting enhances a type of breast cancer treatment — a hormone-signalling pathway and gene-expression changes have key roles. Stephen D. Hursting is in the Department ...

Among more than 4,000 patients with hormone receptor (HR)-positive disease, 3-year invasive disease-free survival (IDFS) ...

Aromatase inhibitors demonstrated superior disease-free survival and time to distant recurrence compared to SERMs in HR+/HER2+ early breast cancer. The benefits of aromatase inhibitors were consistent ...

Giredestrant significantly improved IDFS in ER-positive, HER2-negative early breast cancer, reducing recurrence or death risk by 30% compared to SOC endocrine therapy. Subgroup analyses showed ...

Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...

Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or ...

Menopause after breast cancer can cause symptoms that substantially impact quality of life, making individualized, multidisciplinary care and shared decision-making critical, experts noted during ...

Breast‍‌‍‍‌‍‌‍‍‌ cancer that is dependent on oestrogen is the most frequent type that has been reported worldwide. In general ...

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first ...

Adjuvant giredestrant significantly improved invasive DFS vs. standard-of-care endocrine therapy in patients with early-stage ...

A study published in Nature looks at fasting and hormone therapy response for breast cancer in mice. Dr Charlie Birts, Lecturer in Antibody Therapeutics at the University of Southampton, said: ...